Zhaoke Ophthalmology Acquires Global Rights to Atropine Sulfate Eye Drops

Corporate Action
โดย 红星资本局·Read original
Summary · why it matters

Zhaoke Ophthalmology announced it has acquired the global rights to NVK002 atropine sulfate eye drops, a product designed to slow the progression of myopia in children. Under the agreement, Zhaoke Ophthalmology will obtain global ownership of all intellectual property, trademarks, regulatory filings, clinical data, manufacturing capabilities, and other assets related to NVK002. Previously, the company only held exclusive licenses for Greater China, South Korea, and some Southeast Asian countries. As part of the transaction, Zhaoke Ophthalmology granted the seller a perpetual, royalty-free exclusive license for development and commercialization in the United States. After the acquisition, the company will have full control over the global development, manufacturing, and commercialization of the product. Currently, only Xingqi Ophthalmology has received approval for atropine sulfate eye drops in China. Zhaoke Ophthalmology has submitted marketing applications for two strengths of NVK002 as a modified new drug and a generic drug respectively, with approval expected within the year. Several other pharmaceutical companies, including Hengrui Medicine and Ocumension Therapeutics, are also developing similar products.

Impact on stocks 5

Aging Population± Mixed · 2 stocks
Zhaoke Ophthalmology Limited
6622
▲ PositiveTechnologyrelevance

Zhaoke acquired global rights to NVK002, gaining full control over development and commercialization.

Ocumension Therapeutics 
1477
▼ NegativeCompetitionrelevance

Zhaoke's acquisition strengthens its position in myopia treatment, increasing competition for Ocumension's similar product.

Others± Mixed · 3 stocks
Shenyang Xingqi Pharmaceutical Co Ltd
300573
▲ PositiveCompetitionrelevance

Xingqi is the only approved atropine sulfate eye drop in China, but Zhaoke's pending approval may increase competition; however, Xingqi's established position is a positive.

© 2026 MarketDXNews